PPARA and hypertriglyceridemia: The data in this study suggest that the synergistic effects of Fsp27 silencing and PPARα activation could be exploited therapeutically to reduce diet-induced body weight gain, visceral obesity, hypertriglyceridemia, and steatohepatitis.